The proprietary strain L. paracasei, LPC-S01™ was isolated from the human vagina and as a first step was studied for its probiotic activity in key areas such as safety, acid and bile tolerance, adhesion & GI transit. Based on the results in these key areas, the strain was then evaluated for its probiotic benefit in female health through a randomized, placebo-controlled, double-blind cross-over study (Koirala R et al. FEMS Microbiology Ecology 2020, 96).

Product Key Features

  • Oral dose/dietary supplement
  • Supplied in powder, stick and capsule form
  • Delivers minimum 24B cfu/dose
  • Product has been studied in a human clinical study


  • Favors the balance of the gut microbiota
  • It can contribute to the vaginal microbial balance

Scientific Evidence

Balzaretti S et al. Front. Microbiol. 2015; 6:952

  • Recovery study, that demonstrated the capability of the strain to survive gastrointestinal transit in healthy adults

Koirala R et al. FEMS Microbiology Ecology 2020, 96

  • Randomized, placebo-controlled, double-blind cross-over clinical trial on 40 healthy adult women
  • The probiotic product, favoring the balance of the intestinal microbiota, was also able to contribute to a positive vaginal microbiota modulation:
    • Increase concentrations of key Lactobacilli species including L. crispatus
    • Decreased presence of G. vaginalis (increase G. vaginalis often leads to Bacterial Vaginosis)
    • Decreasing trend of presence of other pathogenic bacteria
    • Strain recovered also in vagina